Unknown

Dataset Information

0

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.

ABSTRACT:

SUBMITTER: Cantini F 

PROVIDER: S-EPMC7313480 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
| S-EPMC7944951 | biostudies-literature
Unknown Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
| S-EPMC9401152 | biostudies-literature
Unknown Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.
| S-EPMC9243240 | biostudies-literature
Unknown Utility of severity assessment tools in COVID-19 pneumonia: a multicentre observational study.
| S-EPMC8813020 | biostudies-literature
Genomics covid-19 study
| PRJEB43387 | ENA
Unknown Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
| S-EPMC8253716 | biostudies-literature
Unknown Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
| S-EPMC11129021 | biostudies-literature
Unknown Supine vs prone position in mild to moderate COVID-19 pneumonia: The impact of proning on computed tomography findings.
| S-EPMC9212665 | biostudies-literature
Unknown Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.
| S-EPMC12819291 | biostudies-literature
Unknown Baricitinib: From Rheumatoid Arthritis to COVID-19.
| S-EPMC8250677 | biostudies-literature